<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40878862</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2578-5745</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>ACR open rheumatology</Title><ISOAbbreviation>ACR Open Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Association of Soluble Immune Checkpoint Molecules PD1 and 4-1BB With CTLA-4Ig Treatment Response in Early Rheumatoid Arthritis.</ArticleTitle><Pagination><StartPage>e70069</StartPage><MedlinePgn>e70069</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70069</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/acr2.70069</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate whether soluble immune checkpoint molecules in blood are associated with the treatment response to disease-modifying antirheumatic drugs in early rheumatoid arthritis (eRA).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study included 328 Swedish treatment-na&#xef;ve patients with eRA from the Nordic Rheumatic Diseases Strategy Trials and Registries (NORD-STAR) study. Patients were randomized into four treatment groups: methotrexate (MTX) combined with CTLA-4Ig (n = 90), anti-tumor necrosis factor (n = 83), anti-interleukin-6 receptor (n = 76), or prednisolone (n = 79). The primary outcome was remission, defined by Clinical Disease Activity Index (CDAI) &#x2264;2.8, assessed at 24 and 48 weeks. Plasma levels of soluble programmed cell death-1 (sPD1) and soluble 4-1BB (s4-1BB) were measured by enzyme-linked immunosorbent assay at baseline and at weeks 24 and 48 after treatment initiation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">High baseline levels of sPD1 and s4-1BB were both associated with CDAI remission at 24 weeks (odds ratio 1.31, 95% confidence interval [CI] 1.04-1.66 and odds ratio 1.50, 95% CI 1.07-2.11, respectively) in patients treated with CTLA-4Ig with MTX, but not in any other treatment groups. Furthermore, baseline levels of sPD1 or s4-1BB together with proportions of PD1<sup>+</sup> T follicular helper (TFh) cells predicted treatment response to CTLA-4Ig with MTX after 48 weeks, achieving 90% and 100% positive predictive value, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">High plasma levels of sPD1 and s4-1BB are associated with good response to CTLA-4Ig with MTX therapy in patients with eRA. A combination of sPD1 or 4-1BB levels and the proportions of PD1<sup>+</sup> TFh cells in blood at baseline has potential for predicting remission after CTLA-4Ig treatment.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Selld&#xe9;n</LastName><ForeName>Tilia</ForeName><Initials>T</Initials><Identifier Source="ORCID">0009-0006-7969-4157</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lend</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5037-5546</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centres, Amsterdam, The Netherlands, and Rheumatology Unit, Center for Molecular Medicine, Department of Medicine, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lampa</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Center for Molecular Medicine, Department of Medicine, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lund Hetland</LastName><ForeName>Merete</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research, Rigshospitalet, Glostrup, Denmark, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd8;stergaard</LastName><ForeName>Mikkel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research, Rigshospitalet, Glostrup, Denmark, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uhlig</LastName><ForeName>Tillmann</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-6881-9552</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordstr&#xf6;m</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine and Rheumatology, Helsinki University and University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xf8;rslev-Petersen</LastName><ForeName>Kim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, S&#xf8;nderborg, Denmark, and Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gudbj&#xf6;rnsson</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre for Rheumatology Research, Landspitali University Hospital and Faculty of Medicine, University of Iceland, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gr&#xf6;ndal</LastName><ForeName>Gerdur</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Rheumatology Research, Landspitali University Hospital and Faculty of Medicine, University of Iceland, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gjertsson</LastName><ForeName>Inger</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-9301-4844</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg and Department of Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Vollenhoven</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centres, Amsterdam, The Netherlands, and Rheumatology Unit, Center for Molecular Medicine, Department of Medicine, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maglio</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-3786-5767</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg and Department of Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersson</LastName><ForeName>Kerstin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hultg&#xe5;rd Ekwall</LastName><ForeName>Anna-Karin</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg and Department of Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lundell</LastName><ForeName>Anna-Carin</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0002-4303-8266</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudin</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg and Department of Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2019-01035</GrantID><Agency>Vetenskapsr&#xe5;det</Agency><Country/></Grant><Grant><GrantID>ALF-GBG-717541</GrantID><Agency>ALF agreement</Agency><Country/></Grant><Grant><Agency>IngaBritt and Arne Lundberg's foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACR Open Rheumatol</MedlineTA><NlmUniqueID>101740025</NlmUniqueID><ISSNLinking>2578-5745</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>30</Day><Hour>4</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>30</Day><Hour>4</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40878862</ArticleId><ArticleId IdType="pmc">PMC12235049</ArticleId><ArticleId IdType="doi">10.1002/acr2.70069</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990&#x2010;2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis 2019;78(11):1463&#x2013;1471.</Citation><ArticleIdList><ArticleId IdType="pubmed">31511227</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetland ML, Haavardsholm EA, Rudin A, et al; NORD&#x2010;STAR study group. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ 2020;371:m4328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7708829</ArticleId><ArticleId IdType="pubmed">33268527</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd8;stergaard M, van Vollenhoven RF, Rudin A, et al; NORD&#x2010;STAR study group. Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48&#x2010;week clinical and radiographic results of the investigator&#x2010;initiated randomised controlled NORD&#x2010;STAR trial. Ann Rheum Dis 2023;82(10):1286&#x2013;1295.</Citation><ArticleIdList><ArticleId IdType="pubmed">37423647</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke KP, Patterson DG, Liang D, et al. Immune checkpoint receptors in autoimmunity. Curr Opin Immunol 2023;80:102283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10019320</ArticleId><ArticleId IdType="pubmed">36709596</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen MA, Andersen T, Etzerodt A, et al. A disintegrin and metalloprotease&#x2010;17 and galectin&#x2010;9 are important regulators of local 4&#x2010;1BB activity and disease outcome in rheumatoid arthritis. Rheumatology (Oxford) 2016;55(10):1871&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pubmed">27330157</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao DA, Gurish MF, Marshall JL, et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature 2017;542(7639):110&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5349321</ArticleId><ArticleId IdType="pubmed">28150777</ArticleId></ArticleIdList></Reference><Reference><Citation>
Aldridge J, Ekwall AH, Mark L, et al. T helper cells in synovial fluid of patients with rheumatoid arthritis primarily have a Th1 and a CXCR3<sup>+</sup>Th2 phenotype. Arthritis Res Ther
2020;22(1):245.
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566124</ArticleId><ArticleId IdType="pubmed">33066816</ArticleId></ArticleIdList></Reference><Reference><Citation>Bommarito D, Hall C, Taams LS, et al. Inflammatory cytokines compromise programmed cell death&#x2010;1 (PD&#x2010;1)&#x2010;mediated T cell suppression in inflammatory arthritis through up&#x2010;regulation of soluble PD&#x2010;1. Clin Exp Immunol 2017;188(3):455&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5422858</ArticleId><ArticleId IdType="pubmed">28245522</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Walsh AM, Canavan M, et al. Immune checkpoint inhibitor PD&#x2010;1 pathway is down&#x2010;regulated in synovium at various stages of rheumatoid arthritis disease progression. PLoS One 2018;13(2):e0192704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5831027</ArticleId><ArticleId IdType="pubmed">29489833</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurtado JC, Kim SH, Pollok KE, et al. Potential role of 4&#x2010;1BB in T cell activation. Comparison with the costimulatory molecule CD28. J Immunol 1995;155(7):3360&#x2013;3367.</Citation><ArticleIdList><ArticleId IdType="pubmed">7561030</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldridge J, Andersson K, Gjertsson I, et al. Blood PD&#x2010;1+TFh and CTLA&#x2010;4+CD4+ T cells predict remission after CTLA&#x2010;4Ig treatment in early rheumatoid arthritis. Rheumatology (Oxford) 2022;61(3):1233&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8889294</ArticleId><ArticleId IdType="pubmed">34009274</ArticleId></ArticleIdList></Reference><Reference><Citation>Glinatsi D, Heiberg MS, Rudin A, et al. Head&#x2010;to&#x2010;head comparison of aggressive conventional therapy and three biological treatments and comparison of two de&#x2010;escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open&#x2010;label, blinded&#x2010;assessor, phase 4 study. Trials 2017;18(1). 10.1186/s13063-017-1891-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-017-1891-x</ArticleId><ArticleId IdType="pmc">PMC5381054</ArticleId><ArticleId IdType="pubmed">28376912</ArticleId></ArticleIdList></Reference><Reference><Citation>Monjo&#x2010;Henry I, Uyaguari M, Nu&#xf1;o L, et al. Circulating Tfh cells are differentially modified by abatacept or TNF blockers and predict treatment response in rheumatoid arthritis. Rheumatology (Oxford) 2025:64(2):517&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">38321365</ArticleId></ArticleIdList></Reference><Reference><Citation>
Anang DC, Ramwadhdoebe TH, H&#xe4;hnlein JS, et al. Increased frequency of CD4<sup>+</sup> follicular helper T and CD8<sup>+</sup> follicular T cells in human lymph node biopsies during the earliest stages of rheumatoid arthritis. Cells
2022;11(7):1104.
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8997933</ArticleId><ArticleId IdType="pubmed">35406668</ArticleId></ArticleIdList></Reference><Reference><Citation>Greisen SR, Rasmussen TK, Stengaard&#x2010;Pedersen K, et al. Increased soluble programmed death&#x2010;1 (sPD&#x2010;1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. Scand J Rheumatol 2014;43(2):101&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">24182347</ArticleId></ArticleIdList></Reference><Reference><Citation>Greisen SR, Kragstrup TW, Thomsen JS, et al. The programmed death&#x2010;1 pathway counter&#x2010;regulates inflammation&#x2010;induced osteoclast activity in clinical and experimental settings. Front Immunol 2022;13:773946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8959817</ArticleId><ArticleId IdType="pubmed">35356000</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel J, Schwarz H. Expression of soluble CD137 correlates with activation&#x2010;induced cell death of lymphocytes. Cytokine 2000;12(6):742&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">10843756</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>